上海瑞齐生物科技有限公司作者
Anti-CD25抗体说明书
资料类型 | jpg文件 | 资料大小 | 3654 |
下载次数 | 100 | 资料图片 | 【点击查看】 |
上 传 人 | 上海瑞齐生物科技有限公司 | 需要积分 | 0 |
关 键 词 | Anti-CD25抗体说明书 , Anti-CD25抗体说明书 , Anti-CD25抗体说明书 |
- 【资料简介】
Anti-CD25抗体说明书
Quantity size: 0.2ml (dilute with pH 7.4 0.01 M PBS or diluent of antibody)Background: CD25(IL2) receptor alpha (IL2RA) and beta (IL2RB) chains, together with the common gamma chain (IL2RG), constitute the high-affinity IL2 receptor. Homodimeric alpha chains(IL2RA) result in low-affinity receptor, while homodimeric beta (IL2RB) chains produce a medium-affinity receptor. Normally an integral-membrane protein, soluble IL2RA has been isolated and determined to result from extracellular proteolyisis. Alternay-spliced IL2RA mRNAs have been isolated, but the significance of each is presently unknown.Anti-CD25抗体说明书Specificity: ·anti- CD25 is a rabbit monoclonal antibody unconjugated·specific for CD25 of rat·epitope mapping near the amino terminus of CD25 ofrat origin· use for western blotting, elisa, immunoprecipitationand immunohistochemistry· Protein A affinity chromatography purification, purity :>95%· Isotype: IgG· mol wt: 82kDaApplication: · Western blotting: 1:100-500· Immunohistochemistry: 1:100-500· ELISA: 1:500-1000· Optimal working dilutions must be determined by the end user.Storage: Store at –20 ºC for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20ºC. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 ºC.Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.Anti-CD25抗体说明书
- 凡本网注明"来源:环保在线"的所有作品,版权均属于环保在线,转载请必须注明环保在线,https://www.hbzhan.com。违反者本网将追究相关法律责任。
- 企业发布的公司新闻、技术文章、资料下载等内容,如涉及侵权、违规遭投诉的,一律由发布企业自行承担责任,本网有权删除内容并追溯责任。
- 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
- 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。